摘要
目的：通过探讨泮托拉唑在临床中应用的安全性评价和风险管理评估，提高第三代质子泵抑制剂药物的临床应用水平。方法：大规模临床回顾性研究，纳入我院2013年1月至2014年11月使用泮托拉唑及奥美拉唑的患者，观察药物不良反应的发生率及不良症状的发生情况；老年患者的不良反应及危重性不良反应发生情况；对过量及长期治疗的不良反应进行分析，初步建立风险管理的处理方案。结果：泮托拉唑不良反应的发生率、不良症状的发生情况低于奥美拉唑；老年患者的发生率不会高于年轻患者，危重性不良反应发生情况不高；过量及长期治疗的不良反应不会增高；医院建立专门的风险管理体系，可以有效降低药物风险。结论：泮托拉唑可以安全高效快速抑制胃酸分泌，临床中健全的风险管理体系可以有效合理使用药物。
Abstract
Objective: To investigate the safety evaluation and risk management assessment of pantoprazole in clinical applications, improve the clinical level third generation proton pump inhibitor drugs. Methods:A retrospective study of large- scale clinical inclusion in our hospital from January 2013 to November 2014 using the patient pantoprazole and omeprazole, the incidence of adverse drug re-actions observed in the incidence and adverse symptoms;elderly patients adverse reactions and adverse reactions critical of occurrence;to overdose and adverse long- term treatment were analyzed initially established treatment options for risk management. Results:The inci-dence of adverse reactions with pantoprazole, the incidence of adverse symptoms of less than omeprazole;incidence in elderly patients is not higher than in younger patients, the incidence of severe adverse reactions is not high;excessive and long- term treatment adverse re-actions are not increased;hospitals to establish specialized risk management system can effectively reduce the risk of medication. Conclu-sion:pantoprazole can safely and efficiently inhibit gastric acid secretion fast, clinical sound risk management system can be effective and rational use of drugs.
关键词
泮托拉唑/安全性评价/风险管理/临床应用Key words
pantoprazole/safety evaluation/risk management/clinical application引用本文复制引用
出版年
2015
NETL
NSTL
万方数据